Signatures of mutation and selection in the cancer genome

被引:541
作者
Bignell, Graham R. [1 ]
Greenman, Chris D. [1 ]
Davies, Helen [1 ]
Butler, Adam P. [1 ]
Edkins, Sarah [1 ]
Andrews, Jenny M. [1 ]
Buck, Gemma [1 ]
Chen, Lina [1 ]
Beare, David [1 ]
Latimer, Calli [1 ]
Widaa, Sara [1 ]
Hinton, Jonathon [1 ]
Fahey, Ciara [1 ]
Fu, Beiyuan [1 ]
Swamy, Sajani [1 ]
Dalgliesh, Gillian L. [1 ]
Teh, Bin T. [2 ]
Deloukas, Panos [1 ]
Yang, Fengtang [1 ]
Campbell, Peter J. [1 ]
Futreal, P. Andrew [1 ]
Stratton, Michael R. [1 ,3 ]
机构
[1] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England
[2] Van Andel Inst, Grand Rapids, MI 49503 USA
[3] Inst Canc Res, Sutton SM2 5NG, Surrey, England
基金
英国惠康基金;
关键词
SOMATIC FRAMESHIFT MUTATIONS; CANDIDATE TUMOR-SUPPRESSOR; FRAGILE SITE STABILITY; COPY NUMBER VARIATION; GLIOBLASTOMA-MULTIFORME; CHROMOSOME FRAGILITY; LUNG ADENOCARCINOMA; COLORECTAL CANCERS; COLON CANCERS; GENE;
D O I
10.1038/nature08768
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The cancer genome is moulded by the dual processes of somatic mutation and selection. Homozygous deletions in cancer genomes occur over recessive cancer genes, where they can confer selective growth advantage, and over fragile sites, where they are thought to reflect an increased local rate of DNA breakage. However, most homozygous deletions in cancer genomes are unexplained. Here we identified 2,428 somatic homozygous deletions in 746 cancer cell lines. These overlie 11% of protein-coding genes that, therefore, are not mandatory for survival of human cells. We derived structural signatures that distinguish between homozygous deletions over recessive cancer genes and fragile sites. Application to clusters of unexplained homozygous deletions suggests that many are in regions of inherent fragility, whereas a small subset overlies recessive cancer genes. The results illustrate how structural signatures can be used to distinguish between the influences of mutation and selection in cancer genomes. The extensive copy number, genotyping, sequence and expression data available for this large series of publicly available cancer cell lines renders them informative reagents for future studies of cancer biology and drug discovery.
引用
收藏
页码:893 / U61
页数:8
相关论文
共 40 条
  • [11] Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions
    Gorgoulis, VG
    Vassiliou, LVF
    Karakaidos, P
    Zacharatos, P
    Kotsinas, A
    Liloglou, T
    Venere, M
    DiTullio, RA
    Kastrinakis, NG
    Levy, B
    Kletsas, D
    Yoneta, A
    Herlyn, M
    Kittas, C
    Halazonetis, TD
    [J]. NATURE, 2005, 434 (7035) : 907 - 913
  • [12] PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data
    Greenman, Chris D.
    Bignell, Graham
    Butler, Adam
    Edkins, Sarah
    Hinton, Jon
    Beare, Dave
    Swamy, Sajani
    Santarius, Thomas
    Chen, Lina
    Widaa, Sara
    Futreal, P. Andy
    Stratton, Michael R.
    [J]. BIOSTATISTICS, 2010, 11 (01) : 164 - 175
  • [13] Roles of FHIT and WWOX fragile genes in cancer
    Iliopoulos, D
    Guler, G
    Han, SY
    Druck, T
    Ottey, M
    McCorkell, KA
    Huebner, K
    [J]. CANCER LETTERS, 2006, 232 (01) : 27 - 36
  • [14] ANALYSIS OF THE P16 GENE (CDKN2) AS A CANDIDATE FOR THE CHROMOSOME 9P MELANOMA SUSCEPTIBILITY LOCUS
    KAMB, A
    SHATTUCKEIDENS, D
    EELES, R
    LIU, Q
    GRUIS, NA
    DING, W
    HUSSEY, C
    TRAN, T
    MIKI, Y
    WEAVERFELDHAUS, J
    MCCLURE, M
    AITKEN, JF
    ANDERSON, DE
    BERGMAN, W
    FRANTS, R
    GOLDGAR, DE
    GREEN, A
    MACLENNAN, R
    MARTIN, NG
    MEYER, LJ
    YOUL, P
    ZONE, JJ
    SKOLNICK, MH
    CANNONALBRIGHT, LA
    [J]. NATURE GENETICS, 1994, 8 (01) : 22 - 26
  • [15] p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a
    Krimpenfort, Paul
    IJpenberg, Annemieke
    Song, Ji-Ying
    van der Valk, Martin
    Nawijn, Martijn
    Zevenhoven, John
    Berns, Anton
    [J]. NATURE, 2007, 448 (7156) : 943 - U11
  • [16] PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
    Li, J
    Yen, C
    Liaw, D
    Podsypanina, K
    Bose, S
    Wang, SI
    Puc, J
    Miliaresis, C
    Rodgers, L
    McCombie, R
    Bigner, SH
    Giovanella, BC
    Ittmann, M
    Tycko, B
    Hibshoosh, H
    Wigler, MH
    Parsons, R
    [J]. SCIENCE, 1997, 275 (5308) : 1943 - 1947
  • [17] Two levels of protection for the B cell genome during somatic hypermutation
    Liu, Man
    Duke, Jamie L.
    Richter, Daniel J.
    Vinuesa, Carola G.
    Goodnow, Christopher C.
    Kleinstein, Steven H.
    Schatz, David G.
    [J]. NATURE, 2008, 451 (7180) : 841 - U11
  • [18] Chromosome 5q deletion and epigenetic suppression of the gene encoding α-catenin (CTNNA1) in myeloid cell transformation
    Liu, Ting Xi
    Becker, Michael W.
    Jelinek, Jaroslav
    Wu, Wen-Shu
    Deng, Min
    Mikhalkevich, Natallia
    Hsu, Karl
    Bloomfield, Clara D.
    Stone, Richard M.
    DeAngelo, Daniel J.
    Galinsky, Ilene A.
    Issa, Jean-Pierre
    Clarke, Michael F.
    Look, A. Thomas
    [J]. NATURE MEDICINE, 2007, 13 (01) : 78 - 83
  • [19] Human chromosome fragility
    Lukusa, T.
    Fryns, J. P.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS, 2008, 1779 (01): : 3 - 16
  • [20] INACTIVATION OF THE TYPE-II TGF-BETA RECEPTOR IN COLON-CANCER CELLS WITH MICROSATELLITE INSTABILITY
    MARKOWITZ, S
    WANG, J
    MYEROFF, L
    PARSONS, R
    SUN, LZ
    LUTTERBAUGH, J
    FAN, RS
    ZBOROWSKA, E
    KINZLER, KW
    VOGELSTEIN, B
    BRATTAIN, M
    WILLSON, JKV
    [J]. SCIENCE, 1995, 268 (5215) : 1336 - 1338